

Biocon Limited CORPORATE PRESENTATION

December 2022

Meta morphosis **Biocon 5.0**



Biocon is a technologyenabled, future-ready, global biopharmaceuticals leader driven by an unwavering purpose to enhance healthcare worldwide through high quality, affordable therapies that can lower costs, increase access and improve treatment outcomes.

GENOMIC INSPIRATION

queil track





To enhance global healthcare through innovative and affordable biopharmaceuticals for patients, partners and healthcare systems across the globe.



- Integrity & Ethical Behavior
- Performance driven Work Culture
- Value Creation through Innovation & Differentiation
- Quality through Compliance & Best Practices
- Collaboration, Team-Work & Mutual Respect

The Biocon Manifesto

SBiocon

As a committed stakeholder of the global health agenda under the UN Sustainable Development Goals (SDGs), Biocon has drawn up a manifesto to deliver on its commitment to universal healthcare.



accessibility

- Use our science, scale and expertise to enhance access to essential drugs for patients on the lowest rung of the economic ladder
- Uncover new medical insights aimed at expanding the scope of therapy to address unmet needs

availability

- Build strategic global and regional partnerships to make high-quality biopharmaceuticals available to the maximum number of people
- Create a robust portfolio of 'blockbuster' drugs with the potential to benefit a billion patients



affordability

- Focus on the kind of innovation that adds the condition of affordability to accessibility
- Bring competition for expensive innovator medicines through our generics and biosimilars



assurance

- Demonstrate the highest levels of ethics, compliance and governance
- Assure continuous supply of highquality products conforming to international regulatory standards

Biocon At A Glance





Rs 83,967 mn | \$1.1 bn Revenue*



1,300+ Patents



50+ cGMP approvals from International regulatory agencies



120+

Countries where our products are available




Ranked 8

15,000+

Total Employees

Among Top 10 Global Biotech Employers by Science magazine

Our Business Evolution Over The Years





Ş\$ Biocon

Differentiated Pipeline of Complex Generics, Biosimilars



GENERICS





BIOSIMILARS







Business Segments

Our Growth Verticals



Aligned to Global Imperative of Driving Greater Health Equity

From pipeline to production, drug discovery to drug delivery, we bring differentiated, high-quality and affordable healthcare products & services globally




Ensuring access through quality, affordability, reliability



A unique, fully integrated global biosimilars enterprise making a difference to patients' lives globally



Partnering to deliver innovative scientific solutions



Pushing scientific boundaries to deliver impactful innovations








Our Biosimilars Business



Biocon Biologics At A Glance





Includes Adalimumab and Etanercept which have been in-licensed by Viatris and Biocon Biologics has economic interest ^ MAT June 2022



		Emerging Markets	Advanced Markets
Biosimilar Value Chain	Product Development	\checkmark	\checkmark
	Clinical Trials	\checkmark	\checkmark
/alue (Regulatory	\checkmark	\checkmark
nilar /	Manufacturing	\checkmark	\checkmark
Biosin	Supply Chain	\checkmark	\checkmark
	Commercialization	\checkmark	

iocon

Acquired capabilities post acquisition of Viatris' biosimilars business





End-to-End Global Scale Capabilities



R&D	MANUFACTURING	COMMERCIALIZATION		
 Process & Product Development 	 Mammalian & microbial tech platforms 	 Wide commercial footprint across advanced and emerging markets 		
 Analytical & Bioanalytical Capabilities 	 Manufacturing facilities in India & Malaysia 	 8* products commercialized globally 		
 Pre-clinical & Clinical Development 	 Drug Substance, Drug Product & Devices Capabilities for insulins & monoclonal antibodies 	 Hybrid model: Direct presence + Network of partners & distributors 		
 Intellectual Property 	 Facilities approved by major international regulators including U.S. FDA & EMA 			
 Regulatory Sciences 				



Comprehensive Portfolio to Address Global Biocon Biologics Disease Burden

Transforming Healthcare. Transforming Lives.




Today	< 2 years	2-4 years	>4 years
 bPegfilgrastim bTrastuzumab bBevacizumab (EU) bGlargine 100 IU bAspart (Canada) bAdalimumab¹ (EU) bEtanercept¹ (EU) rh-Insulin 	 bBevacizumab (US) bAspart (US) bAdalimumab¹ (US) rH-Insulin (US) Vaccines² (SILS collaboration) 	 bAflibercept³ bUstekinumab bDenosumab 	 bPertuzumab bGlargine 300 IU Seven undisclosed programs
Comme	ercialized in Global 08 Markets	3 20 Biosimilars Portfolio	in our

BBL's portfolio targets to unlock a ~USD 70 Billion addressable market

1. BBL has acquired Viatris' global rights to in-licensed assets | 2. Subject to completion of SILS alliance | 3. BBL has acquired Viatris' global rights to partnered asset

Biocon BiologicsSetting New Benchmarks in BiosimilarsTransforming Healthcare. Transforming Lives.Globally





Achieved many 'firsts' in the biosimilars space, ahead of the biosimilars regulatory pathways being defined in many countries

Biocon Biologics
Transforming Lives.Fully Integrated, Global Scale Manufacturing
Facilities



- Proprietary *Pichia pastoris*, mammalian CHO & NSO cell-based platforms
- Drug Substance, Drug Product & Devices
 Manufacturing Capabilities for Insulins, mAbs
- Ranked among Top 15 Global Biopharma Players in terms of Bio-Manufacturing Capacity
- >USD 1 Billion invested in building global manufacturing scale for biologics

Certified By:




















B3: India's First Biopharma Facility Awarded by ISPE








350K Sqft. facility with 4M safe

3.5x current capacity



Historic Acquisition of Viatris' Global Biosimilars Business: November 2022



iocon



Strategic Alliance with SILS for Vaccines in Infectious Diseases

3



1 Access to 100 mn doses of vaccines annually for 15 years Commercialization rights of the SILS portfolio for global markets

Committed revenues and related margins from H2 FY23



~15% stake at a post-money valuation of ~USD 4.9 billion

Adding vaccines to our biosimilars portfolio





S Biocon

Providing World Class Treatment Options Across Therapies; Benefitted 2.5+ Mn Patients' Lives in India



Patient numbers as on March 31, 2022






Our Generics Business

Generics Business At A Glance





Growing Portfolio of Active Pharmaceutical Ingredients (APIs)



Leadership in fermentation-based APIs



Among world's largest manufacturers of statins & immunosuppressant APIs



Balanced portfolio: Cardiovascular, antidiabetes, immunosuppressants, high potent API & niche molecules



Consistent quality compliance & regulatory approvals track record



Investing in R&D - continuous manufacturing, bio transformation





700+ API customers

40+ APIs



75+ countries served by APIs across US, Europe & large emerging markets



Generics Formulations: Vertically Integrated with In-House APIs



 $\langle \bigcirc \rangle$

Forward integrating portfolio of niche, difficult-to-make APIs into formulations



Portfolio spans Cardiovascular, Metabolics, Oncology, Immunology & Autoimmune indications



Development pipeline includes oral solids (potent & non-potent), topical, parenteral & device dependent products



11 products commercialized in U.S.; now expanding to select European & MoW markets directly & through partners

	Products Launched in U.S.				
1	 Rosuvastatin Calcium 				
2	Simvastatin				
3	 Atorvastatin 				
4	 Pravastatin 				
5	 Labetalol HCl 				
6	 Everolimus 				
7	 Tacrolimus 				
8	 Esomeprazole DR 				
9	 Posaconazole 				
10	 Dorzolamide 				
11	 Mycophenolic Acid 				



Manufacturing Operations

5 state-of-the-art facilities in Bengaluru, Hyderabad and Visakhapatnam

Technology platforms include microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis, HPAPIs

2 new facilities – an immunosuppressants plant and a peptides facility – are presently in the process of being commissioned

Accreditations by regulatory agencies such as US FDA, EMA, COFEPRIS, ANVISA, PMDA, NMPS (South Korea)









Our Novel Biologics Business

Novel Biologics



	As	set	Details	Disease Area		
Pushing scientific	ITOLIZUMAB Novel, Humanized CD6 Antibody		 Partnered with Equillium* Got U.S. FDA's 'fast track' designation for aGVHD and Lupus Got U.S. FDA's 'orphan drug' label for prevention, treatment of aGVHD 	INFLAMMATION (ACUTE GRAFT-VS-HOST DISEASE, LUPUS, ULCERATIVE COLITIS)		
boundaries to deliver impactful			EUA for COVID-19; Phase IV completed	COVID-19		
innovations	BICARA A clinical-stage biotechnology company based in U.S.@					
	BCA101 Fusion Protein	First-in-class EGFR / TGFβ-trap bifunctional antibody	Can target multiple tumor types; has higher local tumor concentration of immuno- modulatory arm resulting in better therapeutic window	IMMUNO-ONCOLOGY		

* Licensed to Equillium for US, Canada, Australia & New Zealand @ Associate company focused on developing Immuno-Oncology assets






Our Research Services Business

Syngene Syngene at a Glance






Syngene Research Services Business



Partnering to Deliver Innovative Scientific Solutions



- Integrated R&D & manufacturing services for small & large molecules, ADCs & oligonucleotides
- World-class R&D and manufacturing infrastructure
- Audited successfully by US FDA, EMA, AAALAC & major life sciences partners
- Talented scientific & techno-commercial teams, led by experienced management
- Listed in India on BSE, NSE since 2015






Financials

* Core EBITDA is EBITDA net of licensing, forex, gain on dilution in Bicara, mark-to-market loss on investments and R&D expense.

Biocon Group: Financial Highlights for FY22

Revenue US\$ 1.1 Billion

		FY 22	FY 21
Revenue	+14%	₹8,397Cr	₹7,398Cr
Core EBITDA*	+18%	₹2,669Cr	₹2,270Cr
% margin		32%	31%
EBITDA	+14%	₹2,183Cr	₹1,907Cr
% margin		26%	26%
PBT Before Exceptional Items	+4%	₹1,094Cr	₹1,055Cr
% margin		13%	14%
Net Profit Before Exceptional Items	-3%	₹722Cr	₹744Cr
% margin		9%	10%









Environment, Social, Governance

ESG: Going Beyond Financials to Have a Positive Impact



Our ESG Strategy Pillars



Improve access to high quality therapeutics to drive 'Patient Equity'

Build an empowering and inclusive workplace creating 'People Equity'



Adapting to a sustainable business operations for 'Environment Equity'



Operate with integrity, transparency and accountability ensuring 'Stakeholder Equity'



Enable underserved communities 'Social Equity'

Monitor Performance \rightarrow Improve Through Initiatives \rightarrow Report Outcomes

ESG: A Culture of Purpose, Ethics & Equity



Three key criteria used to assess performance and policies beyond financials




Environment: Use of resources and impact on the environment



Social: People practices and consideration for the broader community



Governance: Rules and principles used to run the organization



ESG: Recognitions



2021



Among Top 10 Global Pharma & Biotech Employers

Biocon & Biocon Biologics together feature at No 8. Biocon has been on the Top 20 Global Biotech Employers list since 2012

2022 rank	2021 rank	Employer (global HQ)	An innovative leader in the industry	Treats employees with respect	ls socially responsible	Provides employees with autonomy	Has loyal employees
1	1	Insmed (Bridgewater, NJ)	\checkmark	\checkmark	\checkmark		
2	3	Alnylam Pharmaceuticals (Cambridge, MA)	\checkmark	\checkmark	\checkmark		
3	4	Regeneron (Tarrytown, NY)	\checkmark		\checkmark		\checkmark
4	2	Incyte (Wilmington, DE))	\checkmark	\checkmark	\checkmark		
5	6	Syngenta Group (Basel, Switzerland)	\checkmark		\checkmark		\checkmark
6	5	Spark Therapeutics (Philadelphia, PA)	\checkmark	\checkmark	\checkmark		
7	7	Moderna (Cambridge, MA)	\checkmark	\checkmark	\checkmark		
8	12	Biocon Limited (Bangalore, India)	\checkmark		~		\checkmark
9	8	Vertex Pharmaceuticals (Boston, MA)	\checkmark	\checkmark	\checkmark		
10	9	Merck KGaA (Darmstadt, Germany)	\checkmark		\checkmark		\checkmark



Science Top Employer is a Top 20 Global Pharma & Biotech Employers annual ranking by the US based Science Careers Magazine



Corporate Social Responsibility

Empowering Communities




Biocon Foundation's Programs Align with Schedule VII CSR Activities as Notified Under Section 135 of the Companies Act 2013



eLAJ Smart Clinics: ~71,000 patient visits (FY22); COVID-19 support to govt



Biocon Chair: Biosciences training and research at IBAB





Hebbagodi Lake: Revival and maintenance



Specialist Camps

- NCD Camps
- Geriatric Camps
- Well Baby Camps
- Dental Camps



Adding Value, Enhancing Skills



Center of Excellence for Advanced Learning in Applied Biosciences



- A combination of academic and experiential learning
- Scholarship up to 75% on course fee
- **850+** students graduated
- 100% Placement Record

Education Partners:



Developing high-end talent for the Biotech sector **PROGRAMS**

- Biocon-KGI Certificate Program in Biosciences
- BITS Biocon Certificate Program in Applied Industrial Microbiology
- Biocon-KGI Certificate Program in Clinical Development
- Biocon JSS AHER Certificate Program in Global Regulatory Affairs
- Biocon Ramaiah Certificate Program in Quality Control Analytical
- Biocon KGI Certificate Program in Bioscience Management
- Biocon Certificate Program in Faculty Development



THANK YOU

Biocon Biologics Corporate Presentation, Developed by Biocon Group Global Communications Team. Write to us at: <u>BioconGroup.Commn@biocon.com</u>

www.bioconbiologics.com



December 2022